Endothelial NADPH Oxidase-2 Promotes Interstitial Cardiac Fibrosis and Diastolic Dysfunction Through Proinflammatory Effects and Endothelial-Mesenchymal Transition  by Murdoch, Colin E. et al.
Journal of the American College of Cardiology Vol. 63, No. 24, 2014
 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2014.02.572Endothelial NADPH Oxidase-2 Promotes
Interstitial Cardiac Fibrosis and Diastolic
Dysfunction Through Proinflammatory Effects
and Endothelial-Mesenchymal Transition
Colin E. Murdoch, PHD,* Sanjay Chaubey, MBBCH, PHD,* Lingfang Zeng, PHD,*
Bin Yu, PHD,* Aleksander Ivetic, PHD,* Simon J. Walker, BSC,* Davy Vanhoutte, PHD,y
Stephane Heymans, MD, PHD,y David J. Grieve, PHD,* Alison C. Cave, PHD,*
Alison C. Brewer, PHD,* Min Zhang, MD, PHD,* Ajay M. Shah, MD, FMEDSCI*
London, United Kingdom; and Maastricht, the NetherlandsFrom the *K
Cardiovascu
Institute Ma
This researc
RE/08/003)
the Departm
Biomedical
(NHS) Fou
College Hos
no relationsh
Manuscri
2014, acceptObjectives Ting’s College London B
lar Division, London, Uni
astricht (CARIM), Maas
h was funded by the Britis
; the Fondation Leducq T
ent of Health through a
Research Centre award to
ndation Trust in partner
pital NHS Foundation T
ips relevant to the conten
pt received November 8,
ed February 25, 2014.his study sought to investigate the effect of endothelial dysfunction on the development of cardiac hypertrophy
and ﬁbrosis.Background Endothelial dysfunction accompanies cardiac hypertrophy and ﬁbrosis, but its contribution to these conditions is
unclear. Increased nicotinamide adenine dinucleotide phosphate oxidase-2 (NOX2) activation causes endothelial
dysfunction.Methods Transgenic mice with endothelial-speciﬁc NOX2 overexpression (TG mice) and wild-type littermates received
long-term angiotensin II (AngII) infusion (1.1 mg/kg/day, 2 weeks) to induce hypertrophy and ﬁbrosis.Results TG mice had systolic hypertension and hypertrophy similar to those seen in wild-type mice but developed greater
cardiac ﬁbrosis and evidence of isolated left ventricular diastolic dysfunction (p < 0.05). TG myocardium had more
inﬂammatory cells and VCAM-1–positive vessels than did wild-typemyocardium after AngII treatment (both p< 0.05).
TG microvascular endothelial cells (ECs) treated with AngII recruited 2-fold more leukocytes than did wild-type ECs in
an in vitro adhesion assay (p < 0.05). However, inﬂammatory cell NOX2 per se was not essential for the proﬁbrotic
effects of AngII. TG showed a higher level of endothelial-mesenchymal transition (EMT) than did wild-type mice after
AngII infusion. In cultured ECs treated with AngII, NOX2 enhanced EMT as assessed by the relative expression of
ﬁbroblast versus endothelial-speciﬁc markers.Conclusions AngII-induced endothelial NOX2 activation has profound proﬁbrotic effects in the heart in vivo that lead to a diastolic
dysfunction phenotype. Endothelial NOX2 enhances EMT and has proinﬂammatory effects. This may be an
important mechanism underlying cardiac ﬁbrosis and diastolic dysfunction during increased renin-angiotensin
activation. (J Am Coll Cardiol 2014;63:2734–41) ª 2014 by the American College of Cardiology FoundationEndothelial dysfunction accompanies conditions such as
hypertension that predispose to adverse cardiac remodeling
and predicts future cardiovascular morbidity (1). As well asritish Heart Foundation Centre of Excellence,
ted Kingdom; and the yCardiovascular Research
tricht University, Maastricht, the Netherlands.
h Heart Foundation (grants RG/08/011/25922,
ransatlantic Network of Excellence Award; and
National Institute for Health Research (NIHR)
Guy’s & St Thomas’ National Health Service
ship with King’s College London and King’s
rust. The authors have reported that they have
ts of this paper to disclose.
2013; revised manuscript received February 22,modulating vascular function, the endothelium has direct
effects on cardiac function (2–4). Pioneering work by
Brutsaert (3) and co-workers demonstrated that cardiac
endothelial cells (ECs) directly inﬂuence myocardial con-
traction, a concept later conﬁrmed in humans in vivo (5).See page 2742The importance of endothelial-cardiomyocyte crosstalk has
been demonstrated in several disease settings (3,6). How-
ever, the role of endothelial dysfunction in the pathogenesis
of adverse cardiac remodeling caused by increased renin-
angiotensin activation remains unclear.
Abbreviations
and Acronyms
AngII = angiotensin II
BM = bone marrow
BP = blood pressure
CMEC = coronary
microvascular endothelial
cell
EC = endothelial cell
EMT = endothelial-
mesenchymal transition
LV = left ventricular
mRNA = messenger
ribonucleic acid
NOX = nicotinamide adenine
dinucleotide phosphate
(NADPH) oxidase
ROS = reactive oxygen
species
TG = transgenic
VCAM = vascular cell
adhesion molecule
JACC Vol. 63, No. 24, 2014 Murdoch et al.
June 24, 2014:2734–41 Endothelial NOX2 Enhances Cardiac Fibrosis
2735A major driver of endothelial dysfunction is the reactive
oxygen species (ROS)–generating enzyme, nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase-2
(NOX2), which is activated by angiotensin II (AngII)
and other agonists (7). NOX2 is expressed in endothelium,
as well as cardiomyocytes, adventitial ﬁbroblasts, inﬂam-
matory cells, and conduit vascular smooth muscle cells.
Vascular NOX2 expression and activity are increased in
hypertension, in which NOX2 modulates intracellular
signaling pathways that promote vascular remodeling,
contributes to vasodilator dysfunction through superoxide-
mediated inactivation of nitric oxide, and may have
proinﬂammatory effects (7).
To investigate the pathophysiological roles of endo-
thelial NOX2, the authors generated a transgenic mouse
model with endothelial-speciﬁc NOX2 overexpression
(TG) (8). This model has a 2-fold increase in endo-
thelial NOX2 protein levels and displays augmented
NOX2 activation in response to AngII. Here, we used
this model to investigate the effects of endothelial
NOX2 activation on the development of cardiac hyper-
trophy, ﬁbrosis, and dysfunction during chronic AngII
elevation.
Methods
Detailed methods are provided in the Online Appendix.
Animal experiments complied with U.K. Home Of-
ﬁce regulations. Male TG mice (8) were compared with
wild-type littermates. Chimeric mice were generated by
bone marrow (BM) transplantation (9). AngII (1.1 mg/
kg/day) or vehicle was infused via osmotic minipumps.
Blood pressure (BP) was measured by radiotelemetry or
tail-cuff plethysmography (10). Left ventricular (LV)
pressure-volume relationship measurements and echo-
cardiography were performed as described (11). Cardiac
ﬁbrosis was quantiﬁed in Picrosirius Red–stained
parafﬁn sections, whereas immunostaining was per-
formed in cryosections. LV homogenate NOX activity
was measured using lucigenin-enhanced chemilumines-
cence (12).
In vitro leukocyte adhesion to coronary microvascular
endothelial cells (CMECs) from TG or wild-type mouse
hearts was studied in a ﬂow chamber (13), with or without
AngII (0.1 mmol/l, 4 h). To assess endothelial-mesenchymal
transition (EMT), cultured human aortic ECs were infected
with Ad.bGal or Ad.NOX2 virus and were then treated with
0.1 mmol/l AngII or vehicle for up to 5 days. Co-culture
experiments with ECs and ﬁbroblasts were performed in
Transwell dishes (Corning B.V. Life Sciences, Amsterdam,
the Netherlands).
Data are expressed as mean  SEM. Comparisons were
made by repeated measures analysis of variance (ANOVA),
2-way ANOVA with Bonferroni post-hoc testing, 1-way
ANOVA, or Student t test, as appropriate; p < 0.05 was
considered signiﬁcant.Results
Effects of endothelial NOX2
overexpressiononangiotensinII–
induced hypertension and cardiac
hypertrophy. Long-term AngII
infusion for 14 days caused
similar systolic hypertension in
TG and wild-type mice (Online
Fig. 1A). LV NADPH oxidase
activity increased in both AngII-
treated groups, with a signiﬁ-
cantly greater rise in TG mice
(Online Figs. 1B and Online
Fig. 2). AngII infusion induced
a similar increase in left ventricle/
body weight ratio or cardio-
myocyte cross-sectional area in
TG and wild-type mice (Online
Figs. 1C and 1D).
Endothelial NOX2 overexpres-
sion potentiates angiotensin II–
induced cardiac ﬁbrosis. The
extent of AngII-induced ﬁbrosis was signiﬁcantly (w2-fold)
greater in TG than in wild-type hearts (Online Fig. 1E). TG
hearts also had signiﬁcantly higher procollagen I messenger
ribonucleic acid (mRNA) expression than did wild-type
hearts (Online Fig. 1F). Representative examples of the
ﬁbrosis and myocyte hypertrophy are shown in Figure 1.
Left ventricular diastolic dysfunction with preserved
systolic function in endothelial NOX2 TG mice. TG
hearts had signiﬁcantly lower echocardiographic LV end-
diastolic dimensions than did wild-type hearts after long-
term AngII infusion (Online Fig. 3). However, there were
no signiﬁcant differences in indices such as interventricular
septal thickness or ejection fraction. More detailed assess-
ment was undertaken by pressure-volume analysis. Systolic
function assessed by end-systolic elastance or LV dP/dtmax/
end-diastolic volume relation was similar in AngII-treated
wild-type and TG groups (Online Figs. 4A and 4B). LV
end-diastolic volume increased in wild-type mice after
AngII but decreased in TG mice (Online Fig. 4C). LV end-
systolic volume tended to increase in wild-type mice after
AngII treatment but fell signiﬁcantly in TG mice (Online
Fig. 4D). As a result, both stroke volume and stroke work
were signiﬁcantly lower in AngII-treated TG hearts versus
wild-type hearts (Online Fig. 4E, Table 1). Isovolumic LV
relaxation time-constant and LV end-diastolic pressure were
similar in wild-type and TG groups (Table 1). However, LV
diastolic stiffness assessed by the end-diastolic pressure
volume relationship was signiﬁcantly higher in AngII-
treated TG hearts versus wild-type hearts (Online
Fig. 4F). Although there was no difference in systolic BP,
arterial elastance was signiﬁcantly higher in AngII-treated
TG hearts (Table 1). Online Figures 4G and 4H show
representative steady-state pressure-volume loops and the
Figure 1 Representative Myocardial Sections Showing Cardiac Hypertrophy and Fibrosis
(A) Cardiomyocyte borders outlined using wheat-germ agglutinin. Scale bars, 50 mm. (B) Picrosirius Red–stained sections. Scale bars, 100 mm. AngII ¼ angiotensin II;
Sal ¼ saline; TG ¼ transgenic; WT ¼ wild-type.
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2736response to preload reduction in wild-type and TG hearts.
These ﬁndings indicate that TG hearts were smaller and
stiffer than were wild-type hearts after long-term AngII
treatment, thus indicating a phenotype of isolated diastolic
LV dysfunction with preserved systolic function.
Endothelial NOX2 enhances myocardial inﬂammatory
cell inﬁltration. To investigate mechanisms underlying the
increased ﬁbrosis in TG, the authors assessed myocardial
inﬂammatory cell inﬁltration. TG hearts had signiﬁcantly
more CD45þ inﬂammatory cells and Mac3þ cells (macro-
phages) after AngII infusion than did wild-type heartsTable 1 Cardiac Function Assessed by LV Pressu
WT Saline WT
Heart rate, beats/min 552  9 50
LVEDP, mm Hg 7.5  0.7 5.
dP/dtmax, mm Hg/min 7,804  459 8,34
dP/dtmin, mm Hg/min 6,497  406 6,65
Stroke volume, ml 16.7  0.9 22.
End-systolic volume, ml 17.8  1.1 21.
End-diastolic volume, ml 29.5  1.7 39.
Ejection fraction, % 53  1 5
Cardiac output, ml/min/g 105.5  8.1 112.
Stroke work, mm Hg/ml/g 14,472  1,280 17,21
Ea, mm Hg/ml 5.7  0.2 4.
Tau-Weiss, ms 7.4  0.4 6.
dP/dtmax/EDV 261.9  39.6 258.
Ees 4.28  0.38 8.9
EDPVR 0.22  0.03 0.2
Number 10
*p < 0.01 for effect of AngII within the group. yp < 0.001 for comparison of
of the TG AngII group with the WT AngII group. xp < 0.01 for comparison of th
within the group.
AngII ¼ angiotensin II; Ea ¼ arterial elastance; EDV ¼ end-diastolic volume
relation; TG ¼ transgenic; WT ¼ wild-type.(Figs. 2A and 2B, Online Fig. 5). AngII treatment increased
connective tissue growth factor and osteopontin mRNA
levels, but levels were similar in wild-type and TG groups
(Online Fig. 6). There was no difference between groups
in transforming growth factor-beta, tumor necrosis factor-
alpha, monocyte chemotactic protein-1, or endothelin-1
mRNA levels.
To conﬁrm that the effects of endothelial NOX2 on in-
ﬂammatory inﬁltration and ﬁbrosis were ROS dependent,
mice were treated with the antioxidant N-acetylcysteine
concurrent with AngII infusion. BP and cardiac hypertrophyre-Volume Loops in WT and TG Mice
AngII TG Saline TG AngII
9  17 543  14 543  12
0  0.8 6.9  1.1 8.1  2.3
8  365 7,497  529 8,098  435
4  417 6,600  544 6,843  604
8  1.7* 15.4  1 16.3  1.6*
9  3.6 17.4  1.4 13.7  0.9y
9  3.7* 29.0  1.4 25.3  1.5y
7  5 52  4 60  4
0  11.5 91.2  5.0 82.3  8.2z
6  1,888 12,365  865 11,569  1,324z
6  0.4 5.9  0.4 7.0  1.0x
2  0.6 7.4  0.7 7.8  1.2
8  32.0 273.9  73.0 334.8  71.1
1  0.69k 4.78  0.40 8.91  1.28k
5  0.04 0.20  0.02 0.46  0.11*z
10 9 8
the TG AngII group with the WT AngII group. zp < 0.05 for comparison
e TG AngII group with the WT AngII group. kp < 0.001 for effect of AngII
; Ees ¼ end-systolic elastance; EDPVR ¼ end-diastolic pressure volume
Figure 2 Inﬂammatory Cell Inﬁltration In Vivo and Endothelial-Leukocyte Interaction In Vitro
(A, B) Mean number of CD45þ and Mac3þ cells/ﬁeld, respectively. (C) Number of leukocytes adherent to wild-type (WT) or transgenic (TG) endothelial cells with or without
angiotensin II (AngII) treatment (0.1 mM, 4 h) in an in vitro assay. (D) Vascular cellular adhesion molecule-1 (VCAM-1) protein levels in WT and TG endothelial cells treated with
AngII. Representative Western blots (top), mean data (bottom). (E) Number of VCAM-1–positive vessels in myocardial sections from WT and TG. (F) Capillary density in
myocardial sections from WT and TG (capillaries/mm2). *p < 0.05 by 2-way analysis of variance; n ¼ 6 to 8/group. Sal ¼ saline.
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2737were similar in wild-type and TG groups treated with
N-acetylcysteine (Online Fig. 7). N-Acetylcysteine markedly
reduced CD45þ cell number in both wild-type and TG
AngII-treated groups and prevented the development of
ﬁbrosis (Online Fig. 7).
NOX2 enhances endothelial activation and leukocyte-
endothelial interaction. We assessed the interaction
between inﬂammatory cells and NOX2-overexpressing
ECs in an in vitro adhesion assay under ﬂow conditions.
Leukocyte attachment to TG and wild-type CMECs was
low at baseline, but after AngII treatment (0.1 mM, 4 h)
signiﬁcantly more leukocytes attached to TG CMECs
(Fig. 2C). TG CMECs had signiﬁcantly higher vascular cell
adhesion molecule-1 (VCAM-1) protein expression than
did wild-type CMECs after AngII treatment (Fig. 2D). In
line with this, LV sections of TG hearts treated with
long-term AngII infusion had more VCAM-1–positive
blood vessels than did wild-type hearts (Fig. 2E, Online
Fig. 8). There was no difference in capillary density
between TG and wild-type hearts (Fig. 2F).
Inﬂammatory cell NOX2 is not essential for angiotensin
II–induced cardiac ﬁbrosis. Because NOX2 is abundantly
expressed in inﬂammatory cells, the authors investigatedwhether NOX2 in these cells was required for the proﬁbrotic
response to AngII. We used BM transplantation to create
chimeric mice with different NOX2 genotypes in BM and
resident tissue cells: 1) wild-type recipient mice with wild-
type BM (WT:WT); 2) wild-type recipients with BM
from global NOX2 knockout mice (KO:WT); 3) global
NOX2 knockout mice with wild-type BM (WT:KO); 4)
NOX2 TG with TG BM (TG:TG); 5) NOX2 TG with
wild-type BM (WT:TG); and 6) wild-type mice with TG
BM (TG:WT). Successful alteration of NOX2 genotype
after BM transplantation was conﬁrmed by assessing ROS
production in recipient BM and peripheral blood mono-
nuclear cells (Online Fig. 9A).
AngII infusion caused similar increases in BP and hy-
pertrophy among groups (Online Figs. 9B and 9C). AngII-
stimulated cardiac ﬁbrosis was signiﬁcantly lower in global
NOX2 knockout versus wild-type mice, as reported previ-
ously (12) (Online Fig. 10). WT:WT and KO:WT mice
both had ﬁbrosis similar to wild-type mice that did not
undergo BM transplantation (Online Figs. 10A and 10B).
In contrast, WT:KO mice had signiﬁcantly less ﬁbrosis,
similar to knockout mice that did not undergo BM trans-
plantation (Online Figs. 10A and B). Thus, knockout BM
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2738cells did not signiﬁcantly alter AngII-induced ﬁbrosis.
Fibrosis in NOX2 TG:TG mice was similar to that in
WT:TG mice, whereas transplantation of TG BM to wild-
type mice did not increase the level of ﬁbrosis to that in the
TG:TG group (Online Fig. 10A right-hand panels, Online
Fig. 10B). Thus, TG BM cells did not signiﬁcantly alter
AngII-induced ﬁbrosis. Taken together, these results indi-
cate that NOX2 in BM cells is dispensable for the proﬁ-
brotic effects of AngII, and it is NOX2 in the resident tissue
cells that is essential. Furthermore, endothelium-targeted
NOX2 overexpression does not signiﬁcantly alter the ef-
fects of BM cells as compared with wild-type groups.
NOX2 promotes endothelial-mesenchymal transition.
Studies indicate that EMT is an important contributor to
cardiac ﬁbrosis during chronic pressure overload (14). The
authors therefore investigated whether enhancing NOX2
activity in ECs affected EMT. Hearts of AngII-treated
TG mice had signiﬁcantly higher levels of ﬁbroblast-
speciﬁc a-smooth muscle actin and collagen-1 than wild-
type, whereas levels of endothelial-speciﬁc CD31 wereFigure 3 Enhanced Endothelial-Mesenchymal Transition in AngII-Trea
(A) Representative Western blots and mean data for CD31, smooth muscle actin (SMA), a
wild-type (WT) or transgenic (TG) mice. Actin was used as a loading control. *p < 0.05; n
imaged by confocal microscopy. Yellow indicates co-localization of endothelial and mese
cence intensities of the 2 ﬂuorophores along the line indicated in the top panel (TG AngII) a
of endothelial-mesenchymal transition.signiﬁcantly lower (Fig. 3A). Myocardial sections of
AngII-treated TG mice showed increased evidence of
EMT, as indicated by co-localization of endothelial-
speciﬁc and mesenchymal markers, compared with wild-
type mice (Fig. 3B).
To assess the effects of endothelial NOX2 further, the
authors studied cultured human aortic ECs with adenovir-
ally mediated overexpression of NOX2 or b-galactosidase
control and treated the ECs with AngII. AngII caused a
modest increase in ﬁbroblast-speciﬁc markers (ﬁbroblast-
speciﬁc protein-1, a-smooth muscle actin) and a concomi-
tant decrease in endothelial-speciﬁc markers (CD31,
CD144) in control ECs. This transition from endothelial-
to ﬁbroblast-speciﬁc expression was enhanced in NOX2-
overexpressing cells (Fig. 4). NOX2 overexpression per
se caused a small switch from endothelial to ﬁbroblast-
speciﬁc expression in the absence of AngII. Online
Figure 11A shows representative examples of coex-
pression of endothelial-speciﬁc and mesenchymal markers
in NOX2-overexpressing cells after AngII treatment.ted TG Hearts
nd collagen 1 (Coll) levels in cardiac homogenates from angiotensin II (AngII)–treated
¼ 4/group. (B) Myocardial sections co-stained for CD31 (red) and SMA (green) and
nchymal markers. Scale bar, 10 mm. Panels to the right show pixel-by-pixel ﬂuores-
nd conﬁrm a signiﬁcant overlapping pattern between CD31 and SMA that is indicative
Figure 4 Effect of NOX2 on Endothelial-Mesenchymal Transition in Cultured Endothelial Cells
(A) Representative Western blots for CD144, CD31, ﬁbroblast-speciﬁc protein-1 (FSP1), smooth muscle actin (SMA), and NADPH (nicotinamide adenine dinucleotide phosphate)
oxidase-2 (NOX2) levels in endothelial cells overexpressing NOX2 or b-galactosidase (b-gal) and treated with angiotensin II (AngII) (100 nmol/l) or vehicle (control [Con]).
Glyceraldehyde phosphate dehydrogenase (GAPDH) was a loading control. (B) Mean data for CD144 and SMA protein levels. Similar results were observed for CD31 and FSP1.
*p < 0.05; n ¼ 4/group. BSA ¼ bovine serum albumin.
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2739Cellular morphology was signiﬁcantly different after 5 days
of AngII treatment, with NOX2-overexpressing cells
showing a more elongated ﬁbroblast phenotype (Online
Fig. 11B).
Paracrine effects of endothelial cells on ﬁbroblasts? It is
feasible that NOX2 elevation in ECs affects ﬁbroblasts
through the direct effects of ROS or other released factors.
To assess this possibility, we performed experiments in which
human aortic ECs overexpressing NOX2 or b-galactosidase
were co-cultured with ﬁbroblasts (see the supplemental
Methods section in the Online Appendix). Experiments
were performed with and without AngII. No difference was
found between the groups in the ﬁbroblast expression of
procollagen I mRNA or in markers of myoﬁbroblast trans-
formation (Online Fig. 12).Discussion
We investigated the speciﬁc effects of endothelial NOX2
activation on AngII-induced cardiac remodeling and took
advantage of a mouse model with endothelium-targeted
overexpression of NOX2 (8). The 2-fold increase in endo-
thelial NOX2 protein in this model has no basal effects but
enhances AngII-stimulated increases in NOX2 activity. In
the present study, the authors found that in vivo AngII-
induced endothelial NOX2 activation has the following
effects: 1) it enhances the development of cardiac ﬁbrosis
independent of cardiomyocyte hypertrophy and leads to a
phenotype of LV diastolic dysfunction with preserved sys-
tolic function; 2) it promotes myocardial inﬂammatory cell
inﬁltration through increased endothelial expression of
VCAM-1 (i.e., endothelial activation), although NOX2 in
inﬂammatory cells is dispensable for the proﬁbrotic effects;
and 3) it enhances EMT, which contributes to the cardiac
ﬁbrosis. Collectively, these data suggest that NOX2-drivenendothelial dysfunction and activation may comprise an
important mechanism that promotes cardiac ﬁbrosis and LV
diastolic dysfunction in pathological settings of renin-
angiotensin system activation.
Endothelium-cardiomyocyte crosstalk. The cardiac endo-
thelium forms a strategic interface between circulating blood
and myocardial tissue. Crosstalk between cardiac ECs and
cardiomyocytes plays important roles in normal cardiac
development (3,4). The cardiac endothelium also inﬂuences
contractile function in the adult heart (e.g., through paracrine
factors such as nitric oxide and endothelin) (2). Reciprocal
signaling between cardiomyocytes and the myocardial mic-
rovasculature has been found to be important during chronic
pressure overload. For example, signaling from ECs to car-
diomyocytes through the neuregulin-1–ErbB2 axis promotes
cardiomyocyte survival during pressure overload (15), and
angiogenic factors released by cardiomyocytes in the chroni-
cally overloaded heart regulate myocardial capillary density
(11,16). Although these study results support the potential for
endothelial dysfunction to affect cardiomyocyte growth, sur-
vival, and contractile function, the effects on cardiac ﬁbrosis in
the heart under stress are unclear.
Proinﬂammatory effects of endothelial NOX2. Here, we
demonstrate that endothelial dysfunction has a profound
ROS-dependent impact on the development of cardiac
ﬁbrosis, independent of cardiomyocyte hypertrophy. One
mechanism underlying these effects may be the proin-
ﬂammatory properties of activated endothelium. The healthy
endothelium is anti-inﬂammatory and antithrombotic, but
in pathological settings such as renin-angiotensin system
activation, it becomes activated and promotes increased
interaction with circulating inﬂammatory cells (17). Previous
studies suggested that NOX2 is involved in cytokine- and
AngII-induced EC activation and the expression of adhe-
sion molecules such as VCAM-1 (18,19), as well as in
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2740enhanced monocyte binding to ECs under oscillatory shear
stress (20). Here, we found that NOX2-overexpressing
CMECs had a larger increase in VCAM-1 expression af-
ter AngII stimulation than did wild-type CMECs, which
were associated with greater endothelial-leukocyte adhesion
in an in vitro ﬂow assay. Consistent with a similar proin-
ﬂammatory action in vivo, TG myocardium had more
VCAM-1–positive blood vessels and inﬂammatory cells after
AngII treatment than did wild-type myocardium. These re-
sults clearly indicate that AngII-induced endothelial NOX2
activation augments an inﬂammatory response in the heart
in vivo. Whether other cell types (e.g., vascular smooth muscle
cells, pericytes) are also involved is an interesting question.
In addition to ECs, NOX2 is abundant in inﬂammatory
cells, where it is suggested to contribute to oxidative stress
(e.g., in atherosclerosis) (21). NOX2 activation in inﬂam-
matory cells is involved in AngII-induced vascular hyper-
trophy (22). It was therefore possible that NOX2 activation
in inﬁltrating inﬂammatory cells (as well as the endothe-
lium) might be important in the development of cardiac
ﬁbrosis. To dissect the speciﬁc contribution of inﬂamma-
tory cell NOX2 activation, we generated chimeric mice in
which the BM consisted of NOX2-competent or NOX2-
deﬁcient cells. This series of studies demonstrated that
NOX2 activation in inﬁltrating inﬂammatory cells is
dispensable for the development of AngII-induced ﬁbrosis
and that it is NOX2 in recipient heart cells that is essential
for the proﬁbrotic effects. This result suggests that although
NOX2 may be important for certain functions of inﬂam-
matory cells (e.g., phagocytosis, low-density lipoprotein
oxidation in atherosclerosis [21]), it is not essential for all
functions and is dispensable in the setting of AngII-induced
cardiac disease.
Role of endothelial-mesenchymal transition. Another
mechanism by which endothelial dysfunction may promote
cardiac ﬁbrosis is through EMT. The transition of epithelial
cells and ECs to a mesenchymal phenotype is well recognized
to be important in cardiac development. In a landmark study,
Zeisberg et al. (14) showed that EMT makes a signiﬁcant
contribution to pathological cardiac ﬁbrosis during chronic
pressure overload. EC production of endothelin-1 has also
been reported to contribute to EMT in the diabetic heart
(23). We therefore investigated whether endothelial NOX2
activation affects EMT. We found evidence of signiﬁcantly
increased EMT in TG hearts after long-term AngII treat-
ment as compared with wild-type hearts. More deﬁnitive
evidence that endothelial NOX2 promotes EMT was
obtained in cultured ECs in which NOX2 signiﬁcantly
enhanced the transition from endothelial to ﬁbroblast phe-
notype after AngII treatment. These results strongly suggest
that a NOX2-dependent increase in EMT may be a crucial
mechanism that enhances cardiac ﬁbrosis in response to
long-term AngII treatment.
We also tested the possibility that paracrine effects of ECs
on ﬁbroblasts (e.g., through the direct effects of ROS released
by ECs) may contribute to ﬁbrosis. In vitro co-cultureexperiments with ECs and ﬁbroblasts did not provide evi-
dence in support of this possibility. However, a possible
contribution of such a mechanism in vivo cannot be excluded.
Isolated diastolic dysfunction. A striking functional
consequence of endothelial NOX2 overexpression on the
response to chronically elevated AngII was a phenotype of
LV diastolic dysfunction with preserved systolic function,
thus resulting in smaller and stiffer hearts and reduced stroke
volumes in TG mice compared with wild-type mice. This
ﬁnding was documented in TG mice by the gold standard
method of in vivo pressure-volume analysis, which demon-
strated signiﬁcantly increased LV diastolic passive stiffness
in the AngII-treated TG group versus the wild-type group,
whereas load-independent indices of systolic function were
similar in the two groups.
Study limitations. We found no signiﬁcant difference
between the groups in parameters of active LV relaxation
(e.g., the isovolumic relaxation time-constant), and this
ﬁnding suggested that cardiomyocyte relaxation was prob-
ably similar in the two groups. This contractile dysfunction
phenotype is consistent with, and fully explainable by, the
increased ﬁbrosis observed in the TG group independent of
differences in cardiomyocyte hypertrophy. The use of an
endothelium-targeted transgenic model allowed the authors
to study the role of endothelial dysfunction and activation
independent of other changes that occur in the remodeling
heart during increased renin-angiotensin system activation.
As mentioned earlier, NOX2 is also expressed in car-
diomyocytes, and previous studies in cultured cells and
in vivo models showed that cardiomyocyte NOX2 activation
may contribute to the development of AngII-induced car-
diac hypertrophy (12). No difference was found in the extent
of hypertrophy between wild-type and TG groups in the
current study, consistent with the ﬁnding that NOX2 was
overexpressed speciﬁcally in ECs. Therefore, the phenotype
of diastolic LV dysfunction with preserved systolic function
found in the current model was the consequence speciﬁcally
of endothelial dysfunction and activation.
Conclusions
The clinical syndrome of heart failure with preserved ejec-
tion fraction is currently receiving signiﬁcant attention
because of the high prevalence of the condition, controversy
regarding its etiology and pathogenesis, and the lack of
effective therapies (24). Although simple extrapolations
cannot be made from the current study in a murine model to
the clinical setting, the occurrence of a contractile dysfunc-
tion phenotype that apparently closely resembles the cardiac
dysfunction found in human heart failure with preserved
ejection fraction is of great interest. It is notable that pre-
vious human studies suggested that inﬂammation contrib-
utes to enhanced ﬁbrosis in such patients (25), consistent
with the ﬁndings of increased inﬂammatory cell inﬁltration,
ﬁbrosis, and diastolic dysfunction in our study. The current
results raise the intriguing possibility that endothelial
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2741dysfunction and activation, as well as downstream pathways
such as inﬂammation and EMT, may be important mech-
anisms contributing to the development of heart failure with
preserved ejection fraction. If so, this could provide new
therapeutic options to tackle this prevalent condition.
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APPENDIX
For a supplemental Methods section, and ﬁgures and tables, please see the
online version of this article.
